These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20969527)

  • 1. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.
    Bethke TD; Huennemeyer A; Lahu G; Lemmer B
    Chronobiol Int; 2010 Oct; 27(9-10):1843-53. PubMed ID: 20969527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
    Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
    J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
    Bethke TD; Böhmer GM; Hermann R; Hauns B; Fux R; Mörike K; David M; Knoerzer D; Wurst W; Gleiter CH
    J Clin Pharmacol; 2007 Jan; 47(1):26-36. PubMed ID: 17192499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
    Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
    J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
    Eckermann G; Lahu G; Nassr N; Bethke TD
    J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
    Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of roflumilast in children and adolescents.
    Neville KA; Szefler SJ; Abdel-Rahman SM; Lahu G; Zech K; Herzog R; Bethke TD; Gleason MC; Kearns GL
    J Clin Pharmacol; 2008 Aug; 48(8):978-85. PubMed ID: 18508947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
    J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
    Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
    Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
    Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
    Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K
    J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.
    Nassr N; Lahu G; Hünnemeyer A; von Richter O; Knoerzer D; Reutter F; Zech K; Hermann R
    J Clin Pharmacol; 2007 May; 47(5):660-6. PubMed ID: 17374735
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
    Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.
    Huennemeyer A; Nassr N; Bredenbröker D; Lahu G
    Expert Opin Drug Saf; 2011 Jul; 10(4):509-19. PubMed ID: 21585288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers.
    Huang J; Fu CX; Yang XY; Cui C; Yang S; Kuang Y; Guo CX; Hu P; Pei Q; Yang GP
    Drug Des Devel Ther; 2018; 12():4047-4057. PubMed ID: 30538429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
    Li Q; Wang Y; Liu L; Ma P; Ding L
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):371-381. PubMed ID: 27306372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous quantification and pharmacokinetic evaluation of roflumilast and its N-oxide in cynomolgus monkey plasma by LC-MS/MS method.
    Qu H; Zhang K; Fu C; Qiu F
    Biomed Chromatogr; 2021 Feb; 35(2):e4973. PubMed ID: 32840886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
    Nassr N; Lahu G; von Richter O; Reutter F; Knoerzer D; Zech K; Erb KA; Schug B; Blume H; Hermann R
    Br J Clin Pharmacol; 2007 Mar; 63(3):365-70. PubMed ID: 16981901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.